✦ LIBER ✦

Met, IGF1R, and Other New Targets in Upper GI Malignancies

✍ Scribed by Elizabeta C. Popa MD, Manish A. Shah MD

Book ID: 120953399
Publisher: Springer
Year: 2013
Tongue: English
Weight: 159 KB
Volume: 14
Category: Article
ISSN: 1527-2729
DOI: 10.1007/s11864-013-0245-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Exciting New Targets in Lung Cancer Ther

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

✍ Joel W. Neal; Lecia V. Sequist 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 195 KB

Stable interference of EWS–FLI1 in an Ew

Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target

✍ Herrero-Martín, D; Osuna, D; Ordóñez, J L; Sevillano, V; Martins, A S; Mackintos 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 455 KB

Profiling YB-1 target genes uncovers a n

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

✍ Finkbeiner, M R; Astanehe, A; To, K; Fotovati, A; Davies, A H; Zhao, Y; Jiang, H 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 386 KB

P-951 Combined ADM of antisense chemorad

P-951 Combined ADM of antisense chemoradioimmunotherapy(ACRIT) consisting of antiHER2 scFv linked onto high energy radioisotopes and triplex forming oligonucleotides (TFO) targeted to DNMT1 and conjugated to vinorelbine tartrate induce apoptosis in metastatic NSCLC characterised by hypermethylated oncosuppressor genes VHL, p53, p16, RASSF1A, Rar-b2, TIMP3, PTEN, H-cadherin, BRCA2, p14ARF and overexpression of HIF-1, VEGF, MMP-2, MMP-9, Glut-1, IGF1R, bcl-2, cdc25c, Raf-1, TGFa, UPAR, c-met and EGFR

✍ Giannios, J.; Michailakis, E.; Ginopoulos, P. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Books of Interest Emerging Drugs and Tar

Books of Interest Emerging Drugs and Targets for Alzheimer’s Disease. Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism . Edited by Ana Martinez Royal Society of Chemistry , Cambridge, U.K. 2010 . xxiv + 317 pp. 16 × 24 cm. ISBN 978-1-84973-063-1 . $249.00. Emerging Drugs and Targets for Alzheimer’s Disease. Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies . Edited by Ana Martinez Royal Society of Chemistry , Cambridge, U.K. 2010 . xxiv + 301 pp. 16 × 24 cm. ISBN 978-1-84973-064-8 . $249.00. Biopharmaceuticals in Plants. Toward the Next Century of Medicine . By Kathleen Laura Hefferon CRC Press , Boca Raton, FL . 2010 . xvii + 206 pp. 16 × 24 cm. ISBN 13 978-1-4398-0474-2 . $99.95. GPCR Molecular Pharmacology and Drug Targeting . Edited by Annette Gilchrist Wiley , Hoboken, NJ . 2010 . xxi + 520 pp. 16 × 24 cm. ISBN 978-0-470-30778-6 . $149.95. Drug Development Perspectives. Considerations, Challenges, and Strategies . Edited by Nuggehally R. Srinivas HNB Publishing , New York, NY . 2010 . x + 326 pp. 16 × 24 cm. ISBN 978-0-9664286-9-8 . $99.75. Chemoinformatics and Computational Chemical Biology . Edited by Jürgen Bajorath Humana Press/Springer Science , New York, NY . 2010 . x + 588 pp. 18.5 × 26 cm. ISBN 978-1-60761-838-6 . $159.00. Functional Molecules from Natural Sources . Edited by Stephen K. Wrigley , Robert Thomas , Colin T. Bedford , and Neville Nicholson Royal Society of Chemistry , Cambridge, U.K. 2011 . x + 233 pp. 16 × 24 cm. ISBN 978-1-84755-259-4 . £109.99.

📂 Article 📅 2011 🏛 American Chemical Society 🌐 English ⚖ 606 KB